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Graphical abstract 
 
Abstract 
 
Cervical cancer is a leading cause of cancer-related death in women, and 
it is known to have a poor prognosis. This is because, patients develop 
progressive or recurrent tumours after primary treatment, and the major 
reason for tumour recurrence is the presence of cancer stem cells (CSCs). It 
is known that retinoic acid (RA) has potential therapeutic effects on cervical 
cancer. However, the possible mode of action of RA in cervical cancer cells, 
and its relation to CSCs remains elusive. The aim of this research was to 
determine the anticancer effect of RA in cervical cancer cells (HeLa). HeLa 
cells were treated by various concentrations of RA ranging from 5-50µM to 
determine the effect of RA on cell viability, and cell proliferation. Both 
experiments were carried out using Celltiter-glo 2.0 assay and CyQuant NF 
assay, respectively. Apoptosis activity was determined using Caspase-Glo 
3/7 assay. Immunofluorescent staining was conducted to detect the 
expression of differentiation marker (pan-keratin), and stem cell markers 
(CD133 and SSEA4) on untreated and treated HeLa cells with 10µM of RA. 
The findings showed that RA reduced cell viability and proliferation in a 
dose-dependent manner by 12-83% and 22-86%, respectively. However, a 
change in caspase3/7 activity between untreated, and 10µM RA-treated 
Hela cells were not detected indicating absence of apoptotic activity. The 
study also revealed that expression of differentiation marker (pan-keratin) 
was up-regulated, while expressions of stem cell markers (CD133 and SSEA4) 
were down-regulated. In addition, morphology of HeLa cells displayed a 
more differentiated phenotype that is less proliferative upon RA treatment. 
These findings suggest that RA showed its anticancer effect on cervical 
cancer cells by exhibiting cytotoxicity, inhibiting proliferation capacity, and 
inducing differentiation of cervical cancer cells. This finding shows that 
retinoic acid may potentially serve as a potent targeted therapy for cervical 
cancer and other cancers possessing CSCs within its tumors.   
 
Keywords: Cervical cancer, anti-cancer, retinoic acid, cancer stem cells 
(CSCs), differentiation  
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Abstrak 
 
Kanser serviks adalah punca utama kematian di kalangan wanita, dan 
mempunyai prognosis yang kurang efektif. Ini kerana, pesakit mengalami 
tumor progresif selepas rawatan dan menyebab utama tumor progresif 
adalah, disebabkan sel kanser stem (CSC). Ia telah diketahui bahawa, 
retinoic asid (RA) mempunyai kesan terapeutik terhadap kanser serviks. 
Tujuan kajian ini adalah, untuk menyiasat kesan antikanser retinoic asid 
dalam rawaten sel kanser serviks. Dalam kajian ini, sel-sel HeLa telah dirawat 
dengan pelbagai kepekatan RA antara 5-50μM. Kesan retinoid asid 
terhadap viabiliti dan prolifarasi sel HeLa, telah dikaji menggunakan celltiter-
Glo 2.0 assay dan CyQuant NF assay. Manakala, aktiviti apoptosis telah 
dikaji menggunakan Caspase-Glo 3/7 assay. Kesan retinoic asid terhadap 
pelbagai penanda seperti (pan-keratin) dan (CD133 dan SSEA4) telah dikaji. 
RA menunjukkan kesan anti-kanser kanser terhadap sel-sel kanser serviks 
dengan mengurangkan viability sehingga 12-83% dan proliferasi sel kanser 
sehingga 22-86%. Namun, RA tidak menunjukkan aktiviti apoptosis terhadap 
sel kanser. RA meningkatan ekspresi penanda (pan-keratin) dan 
pengurangan eksprasi penanda (CD133 dan SSEA4) dan perbezaan 
morfologi sel HeLa selepas rawatan RA membuktikan kesan anti-kanser RA. 
Kesimpulannya, RA menunjukkan kesan anti-kanser, dengan menghalang 
keupayaan proliferasi dan viabiliti dan mendorong pembezaan sel-sel 
kanser serviks. Oleh itu, asid retinoic berpotensi sebagai terapi sasaran untuk 
kanser serviks. 
 
Kata kunci: Kanser servix, anti-kanser, asid retinoic, sel kanser stem (CSCs), 
pembezaan 
 
© 2019 Penerbit UTM Press. All rights reserved 
  
 
 
1.0  INTRODUCTION 
 
Cervical cancer is the third common female disease 
worldwide after breast and colorectal cancer, with 
about half a million cases a year with 80% cases in 
less-developed countries, and about 25% in 
developing countries [1, 2]. The main cause of 
cervical cancer is the Human papillomavirus (HPV) 
infection [1]. HPV is a virus that is transmitted sexually 
[3]. Although, most HPV infection is harmless and 
clears spontaneously, persistent infection with high-
risk human papillomavirus subtype, especially type 16 
and type 18 greatly increases the risk of cervix 
cancer [4, 5]. HPV virus infects epithelial cells, and 
induce hyperproliferative lesions [6]. 
The current treatment strategies for cervical 
cancer are electro-surgery and cryosurgery (remove 
and cure premalignant lesions), while chemotherapy 
and radiotherapies are usually used for high-risk 
premalignant lesions, and carcinomas [7]. However, 
the major problem with current treatments is that 
patients with cervical cancer showed tumour 
recurrence where the tumour characteristics 
become more malignant after treatment [7]. The 
main reason for tumour recurrence is pressumed to 
be due to the population of cancer stem cell (CSC) 
within the tumour. In the cervix, the de-differentiation 
of mature cells, and mutation of stem cells in normal 
cervical tissue is believed to be the source of cervical 
cancer stem cells [8]. Based on previous studies, 
CSCs have been identified in several cervical 
cancers cell line  such as SiHa, CaLo, C-33A [9]. CSCs 
have properties similar to normal stem cells such as 
self-renewal, slow cycling capacity, multilineage 
differentiation potential, asymmetric division, and 
tumorigenicity [10, 11].  
All traditional chemotherapies target proliferating 
cells, potentially missing the slower dividing CSCs 
within a tumour, allow the CSCs to survive, and be 
resistant to treatment. These abilities of the CSCs are 
responsible for tumour metastasis, relapse, and 
chemo/radio-resistance as a result of reactivation of 
proliferation by the surviving CSCs post treatment 
[12]. Therefore, it is necessary to identify effective 
drugs to target CSC enriched cervical cancer, which 
are still difficult to treat, and lack effective treatment 
for cervical cancer [10]. 
As it is known that stem cells differentiate into 
more matured/specialised cells with limited 
proliferative capacity, current anti-cancer drug 
treatments are focused more on establishing 
differentiation based therapies [13]. The principle of 
differentiation therapies is to convert CSC population 
within a tumour into a more differentiated 
phenotype, and to make them respond to a second 
drug, or therapy that targets differentiated cancer 
cells [13]. 
Retinoic acid is a metabolite of vitamin A. Retinoic 
acid was previously discovered to have potential in 
preventing cancer development. The function of this 
compound in biological processes are maintenance 
of epithelial cell, differentiation, proliferation, and 
apoptosis [14]. It also acts as inhibitors of chemical 
and viral carcinogenesis [14]. Previous studies on 
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retinoic acid showed that it suppressed the growth, 
and development of various types of tumors such as 
skin, bladder, lung, prostate, and breast cancers [15]. 
Besides that, addition of retinoic acid to human 
tumour xenograft in mice resulted in growth arrest, 
and differentiation of tumour cells [16, 17]. Previous 
studies also reported that retinoic acid, a promising 
chemotherapy agent in acute promyelocytic 
leukemia (APL), destroys the fusion oncogene such 
as autophagy [17]. In acute promyelocytic leukemia 
patients, retinoic acid-induced apoptosis mediated 
by paracrine action of tumour-selective death ligand 
TRAIL [18]. Moreover, retinoic acid in combination 
with histone deacetylase inhibitors SL14 has an anti-
tumour effect, and is a therapeutic candidate to 
treat lung cancer [19]. 
Thus, an understanding of anti-cancer effect of 
retinoic acid in cervical cancer cells, is important for 
developing the usage of retinoids in therapeutic 
trials. However, the action/mechamnism of retinoic 
acid in cervical cancer still remains unclear. 
Therefore, this project looks into the anti-cancer 
effect of retinoic acid, and its possible mechanism of 
action based on the ability to  induce apoptosis in 
cervical cancer cells 
 
 
2.0  METHODOLOGY 
 
2.1  Cell Culture 
 
Cervical cancer cell line (Hela cells) were cultured in 
T25 flasks and maintained at 37° and 5% of CO2 in 
DMEM/F12+GlutamaxTM1 (Life Technologies, USA), 
supplemented with fetal calf serum (FCS), and 
antibiotic-antimycotic (100 U/mL penincilin, 100µg of 
streptomycin/0.25µg/ml) (Invitrogen). Cervical 
cancer cell line (Hela cells) was passaged, three 
times a week at 60-70% cell confluency. 
 
2.2  Determination of Cell Viability and Proliferation  
 
60-70% confluency of cell cultures were used to test 
cell viability (cytotoxicity) and proliferation. 4×103 
cells per 100-μl were seeded in a 96-well plate. After 
24 hours of incubation, retinoic acid was added at 
different concentrations (5, 10, 15, 20, 30 and 50μM) 
and incubated for 24 hours. Examination of cell 
viability was done via Celltiter-Glo® 2.0 Assay kit. 100-
μl of celltiter-glo® 2.0 reagent was added per well 
and contents were mixed for 2 minutes on a vortex 
mixer. To stabilize luminescent signal, plate was 
incubated for 10 minutes before the reading was 
taken. Meanwhile, the cell proliferation was 
examined via Cyquant® NF assay kit. Old media was 
removed post 24 hours of RA treatment. Cells were 
then resuspended in 50μL 1×Hank’s Balanced Salt 
Solution (HBSS). 50μl 2× dye binding solution 
(CyQuant) was dispensed into each well containing 
cell culture. The microplate well were covered and 
incubated at 37°c for 2 hours before reading was 
taken. The activity for both the assays was read at 
490nm by installing a blue filter using a GloMax®-Multi 
Microplate Multimode Reader (Promega GloMax®-
Multi Detection System). Experiments were done in 
three independent experiments and the results were 
averaged. 
 
2.3  Caspase-Glo® 3/7 Apoptosis Assay System 
 
Cell cultures of 60-70% confluency were used for the 
apoptosis assay. 4×103 cells per 100-µl were seeded 
in a 96-well plate. The cells were incubated for 24 
hours. After that, 10µM of retinoic acid and 20nM of 
taxol was added, respectively, and the cells were 
again incubated for 24 hours. 10µM of retinoic acid 
was selected as it showed 50% reduction in cell 
proliferation assay. After 24 hours of incubation, 96-
well plate containing cultured cells were equilibrated 
to room temperature. Caspase-Glo® 3/7 reagent 
was added to each well that contained control, 
10µM of retinoic acid, and 20nM of taxol. The plate 
wells were covered and mixed gently, and 
incubated for 2 hours at room temperature. 
Fluorescence intensity of samples was measured at 
490nm by installing a blue filter using a GloMax®-Multi 
Microplate Multimode Reader (Promega GloMax®-
Multi Detection System). Caspase activity 
luminescence (RLU) percentage of apoptosis for 
control (untreated cell) was set to 1% which 
indicated natural apoptosis activity whereas the 
retinoic acid and taxol (positive control; apoptosis 
inducing drug) treated Hela cells apoptotic activity 
levels were normalised to the control.Experiments 
were done in three independent experiments and 
the results were averaged. 
 
2.4  Immunofluorescence Microscopy 
 
2.4.1 Staining of Intracellular Marker (Pan-Keratin) 
and Surface Marker (CD133 and SSEA4) 
 
Hela cells were stained with Intracellular marker (pan-
keratin) to detect the presence of differentiation and 
surface markers (CD133 and SSEA4) to detect the 
stemness via presence of CSCs in untreated, and RA 
treated HeLa cells. In 24-well plates, 4×104 cells per 
500ml were grown separately on coverslips for 24 
hours. 10-µM of retinoic acid was added, and the 
cells were incubated for 24 hours. The cells were then 
fixed with 1% of paraformaldehyde (PFA) in FCS 1% 
for 20 minutes. The over slips were washed once with 
PBS (phosphate-buffered saline) per well, and 
transferred to new 24 well plates. For intracellular 
marker, the cells were permeabilized by adding 0.1% 
of Triton X-100 (Calbiochem) in PBS for 20 minutes, 
and washed once with PBS prior to the addition of 
primary antibody. The primary antibodies anti-
cytokeratin antibody (CK3-6H5 FITC, human), 
(CD133/1-VioBright (TM) FITC) and (anti-SSEA4-FITC, 
human) were added into each well, and incubated 
overnight in a dark area. The cells were washed with 
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PBS. Secondary antibodies, mouse-IgG1- viobright 
FITC, and REA control(s) FITC along with 1:1000 (DAPI) 
for nuclear staining were added to the cells and 
incubated for another 2 hours. The cells were then 
washed with PBS, and the cover-slips were transferred 
on to slides with mounting medium (Dako), and 
sealed with nail polish. Appropriate negative control 
(secondary antibody only) was used for this study. 
The cells were imaged by using an inverted 
immunofluorescence microscopy. 
 
2.5  Statistical Analysis 
 
Statistical and graphical analysis was done in 
Microsoft Excel and GraphPad Prism-7. Paired t-test 
with two-tailed distribution was used to compare 
retinoic acid-treated and untreated cervical cancer 
cells. The results are presented in a mean±SEM for 
(cytotoxicity, cell proliferation and apoptosis 
(caspase activity)). The significance is shown as 
follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 
0.0001. 
 
3.0  RESULTS AND DISCUSSION 
 
3.1 Retinoic Acid Reduces Cell Viability and 
Proliferation of Cervical Cancer Cells 
 
Cell viability of HeLa cells was determined using 
CellTiter-Glo® 2.0 Assay. Based on Figures 1, 2 and 3, 
retinoic acid showed a dose-dependent effect in 
HeLa cells. As shown in Figure 1, retinoic acid at 
doses 5, 10, and 15 µM showed a small decline in cell 
viability, which indicates a minimal level of cytotoxic 
effect in HeLa cells, ranging from 12-21%. However, 
the most significant reduction in cell viability was 
observed at 50µM, (83%, p<0.01), followed by 30µM, 
(59%, p<0.01), and 20µM, (36%, p<0.01). This result 
showed that retinoic acid significantly exhibited 
cytotoxicity effect towards HeLa cells at higher doses 
(20, 30 and 50µM). To elucidate whether retinoic acid 
inhibited cell proliferation, the proliferation activity of 
HeLa cells was determined. 
As shown in Figure 3, cell proliferation capacity 
showed a dramatic decrease in comparison to the 
cell viability at all doses of retinoic acid (5, 10, 15, 20, 
30 and 50µM); 22% (p<0.001), 46% (p<0.05), 59% 
(p<0.05), 62% (p<0.01), 73% (p<0.001) and 86% 
(p<0.0001), respectively. The marked reduction in cell 
proliferation despite being viable may suggest that 
the surviving HeLa cells may have undergone 
differentiation. Based on a previous study it 
demonstrated that inhibition of cell growth can be 
the early indications of induced differentiation in 
cultured neuroblastoma cells [20]. 
In addition, the morphological changes in HeLa 
cells upon retinoic acid treatment showed a more 
differentiated phenotype that is less proliferative (see 
Figure 4). The cell density began to decrease and the 
cells that were exposed to higher doses of retinoic 
acid lost their normal morphology and shape; HeLa 
cells appeared slightly rounded in shape, and 
contracted with the increasing concentration of 
retinoic acid. At 30 and 50µM of retinoic acid, most 
of the cells appeared almost round in shape, which 
can be presumed that the surviving cancer cells 
could be cancer stem cells (CSCs) that are drug 
resistant (see Figure 4). The CSCs are known to live 
longer, are resistant to the effects of drugs, and have 
a quiescent slow-cycling phenotype [12, 21, 22]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Analysis on the effects of growth inhibition activity 
of retinoic acid at increasing concentrations (5, 10, 15, 20, 
30 and 50 μM) on cell viability which was determined by 
cell-titer Glo 2.0 assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Analysis on the effects of growth inhibition activity 
of retinoic acid at increasing concentrations (5, 10, 15, 20, 
30 and 50 μM) on proliferation towards cervical cancer cells 
which was determined by CYQUANT NF assays 
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Figure 3 Analysis on the effects of growth inhibition activity 
of retinoic acid at increasing concentrations (5, 10, 15, 20, 
30 and 50 μM) on cell viability and proliferation towards 
cervical cancer cells. Bar chart showed, retinoic acid 
reduces cell viability and proliferation in cervical cancer 
cells at increasing concentrations 
 
 
Figure 3 shows the morphology of HeLa cells 
cultured with and without 10µM of retinoic acid 
(10µM of retinoic acid showed 50% reduction in cell 
proliferation) after 24 hours of treatment. The images 
were obtained using Nikon eclipse TS 100 inverted 
microscope at 10X magnification; scale bar: 100 μm. 
Experiments were done in triplicate in three 
independent experiments and the results were 
averaged. Bars are presented as mean±SEM (n=3). 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
 
 
 
                
 
 
 
                                                                    
 
control 5µM retinoic acid  
 
10µM retinoic acid 
 
15µM retinoic acid 
 
20µM retinoic acid 
 
30µM retinoic acid 
 
50µM retinoic acid 
 
 
Figure 4 Morphology of HeLa cells post 24 hours treatment 
with 0, 5, 10, 15, 20, 30 and 50 μM of retinoic acid (RA) after 
24 hours. The morphological changes induced by RA 
became increasingly visible and were found to be dose 
dependent. The images were captured at 20X 
magnification; scale bar: 100 μm 
 
3.2 Retinoic Acid Did Not Induce Apoptosis in 
Cervical Cancer Cells  
 
Apoptosis is a physiological function of programmed 
cell death, and is characterised by distinct 
morphological characteristics such as cell shrinkage, 
chromatin condensation, dense cytoplasm, blebbing 
of plasma membrane, loss of nuclear membrane 
integrity, and eventually apoptotic bodies forms [23]. 
10µM of retinoic acid was selected for apoptosis 
assay as it showed 50% reduction in cell proliferation 
assay (Figure 2). Treatment with 10µM of retinoic acid 
(0.98%) showed negligible changes in apoptosis 
induction, while 20nM of taxol (1.71%) showed clear 
and significant increase in caspase3/7 activity which 
indicates apoptosis.  
In general, as shown in Figure 5, a small dose of 
taxol was sufficient to induce apoptosis in HeLa cells, 
while retinoic acid did not induce apoptosis even at 
a higher dose. Thus, this data suggests that retinoic 
acid did not induce caspase -3 /7 activity in HeLa 
cells [24]. The finding from this assay suggest that 
growth suppression induced by retinoic acid does 
not cause the death of cancer (tumour) cells, but the 
cells get arrested during the G1 stage of the cell 
cycle [25]. 
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Figure 5 Apoptosis-inducing ability of retinoic acid (RA) and 
taxol in Apoptosis-inducing ability of retinoic acid (RA) and 
taxol in Hela cervical cancer cells. Bars are presented as 
mean±SEM (n=3) 
 
 
3.3 Retinoic Acid Induces Differentiation of Cervical 
Cancer Cells 
 
Pan-keratin is an epithelial differentiation marker, and 
specifically targets luminal epithelial cells. CD133 is a 
cervical cancer stem cell marker, and highly 
expressed in HeLa cells that display stem-like 
characteristics such as differentiation, anti-apoptotic, 
proliferation, chemo/radio-resistance, self-renewal, 
and tumorigenicity [9]. SSEA4 is a human embryonic 
stem cell marker which displays characteristics as 
indefinite self-renewal and pluripotency [26]. 
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Based on Figure 6, upon retinoic acid treatment, the 
expression of differentiation marker showed an 
increase in pan-keratin. In contrast, expression of 
CD133 and SSEA4 decreased. The 
immunofluorescent staining suggests that, retinoic 
acid may exert its mechanism by inducing 
differentiation, and shifts the cervical cancer cells to 
a more differentiated and less proliferative cell type 
by up-regulating the differentiation marker (pan-
keratin), and down-regulating the stem cells markers 
(CD133 and SSEA4). Previous studies also showed that 
stem cell markers such as SSEA4 are highly expressed 
in CSC enriched tumours while differentiation marker, 
pan-keratin is highly expressed in more differentiated 
cells [27]. Other studies showed that SP cells express 
high expression of CD133 marker that were isolated 
from the HeLa cell line, which shows stem like 
properties such as self-renewal, proliferation, and 
differentiation. These SP cells were found to be 
resistant to chemotherapy [28]. In contrast, SSEA4 
expression in general is known to be 
diminished/down regulated during the differentiation 
process [29].  
Thus, based on the findings of this study, it can be 
concluded that retinoic acid induced differentiation 
by shifting cervical cancer cells towards a more 
differentiated, and less proliferative cell type instead 
of inducing cell death via apoptosis. As more 
differentiated cancer cells are often easier to be 
treated, a second anticancer agent can be used to 
target, and kill the differentiated CSCs post RA 
treatment. These findings also show that retinoic acid 
can be a potent targeted anticancer drug in the 
treatment of cervical as well as other cancers that 
are enriched with cancer stemcells (CSCs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Retinoic acid influences expression of differentiation 
marker (pan-keratin) and stem cell markers (CD133 and 
SSEA4) in cervical cancer cell (HeLa). Stem cell markers 
were down-regulated after treatment with 10μM of retinoic 
acids and differentiation marker was increased after the 
treatment 
 
 
4.0  CONCLUSION 
 
Cervical cancer is a common type of 
gynaecological malignancy, and can result in death 
if left untreated. Intra-tumour genetic heterogeneity 
in cervical cancer leads to metastasis, poor 
chemo/radio-therapy response, and recurrence of 
the disease. The major factor that contributes to the 
recurrence of the cancer in cervical cancer is the 
presence of cancer stem cell (CSCs). This study 
showed that retinoic acid exerts anticancer 
properties by effectively reducing cell proliferation 
and cell viability of HeLa cells. In addition, a down-
regulation of cancer stem cell marker and an up-
regulation of differentiation marker expression as well 
as morphological changes in HeLa cells in the 
presence of retinoic acid, correlate well with the 
significant anticancer properties of retinoic acid. 
Therefore, the findings of this study show that retinoic 
acid may potentially serve as a potent targeted 
therapy for cervical cancer. Thus, retinoic acid in 
combination with other anticancer drugs might act 
efficiently, or additively to suppress the growth of 
tumour/cancer, and provide an effective targeted 
therapy for cervical cancer. These findings also 
provide a new avenue for adjuvant treatment in 
treating cancers that are enriched with CSCs. 
However, further studies on retinoic acid are required 
to find the exact mechanism of action for better 
FITC Merged ITC 
Negative control 
Untreated HeLa cells 
(merged) 
Treated HeLa cells 
(merged) 
CD133 
SSEA4 
Pan-keratin 
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understanding, and improvement of cervical cancer 
treatment.  
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